Thomas Marron, MD, PhD, on the Value of Neoantigen Vaccines and Future Research

Video

Marron spoke about the value that neoantigen vaccines can provide by studying T-cell responses and the characteristics of lymphoid response to antigens.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork® at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 about the value that neoantigen vaccines can provide to patients with cancer, even if the process is expensive and time consuming.

Transcription:

I’ll be honest, these neoantigen vaccines are very time consuming and expensive, but I think that they teach us a lot not only by validating these pipelines, but also by studying the T-cell responses and the characteristics of the lymphoid response to these antigens. It’s going to inform our next generation of vaccines, whether that be personalized vaccines. Obviously, personalized vaccines are ideal because we can vaccinate and develop a polyclonal response to a patient’s tumor. But even if we’re looking at off-the-shelf shared neoantigen vaccines, there [are] a lot of companies working on EGFR vaccines, KRAS vaccines, p53 vaccines, and maybe a combination thereof, those all being driver mutations that are seen across many different malignancies. Using the pipeline that we use, and also studying the samples from these patients is really going to help push those fields forward as well.

Reference:

Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB048.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content